Table 3.
Recurrence-free survival (RFS): median RFS and univariate and multivariate analysis according to patient and disease characteristics.
| RFS | Univariate HR | p-Value * | Multivariate HR | |
|---|---|---|---|---|
| Median (95% CI) | HR (95% CI) | HR (95% CI) | ||
| Sex | ||||
| - Male | 37.1 (22.9–51.4) | Reference | ||
| - Female | 26.9–14.2–39.5) | 1.13 (0.79–1.62) | 0.49 | |
| Age (years old) | 0.39 | |||
| - <65 | 33.4 (25.7–41) | Reference | ||
| - 65–74 | 79.9 (79.9-NR) | 0.96 (0.66–1.39) | 0.76 | |
| - ≥75 | 15.4 (0–37.4) | 1.47 (0.9–2.4) | 0.12 | |
| Primary site of melanoma | 0.01 | 2.64 (1.15–6.01) p = 0.02 |
||
| - Cutaneous melanoma | 43.4 (26.1–60.7) | Reference | ||
| - Acral melanoma | 14.5 (6.3–22.6) | 1.72 (0.96–3.08) | 0.07 | |
| - Mucosal melanoma | 9.2 (1.8–16.6) | 3.15 (1.37–7.25) | <0.01 | |
| - Unknown origin | 28 (6.2–49.7) | 1.39 (0.7–2.76) | 0.35 | |
| BRAF status | ||||
| - BRAF wild type | 33.2 (23.18–43.2) | Reference | ||
| - BRAF V600 mutant | 19.1 (3.1–35) | 1.3 (0.9–1.84) | 0.16 | |
| Breslow index (mm) | 0.81 | |||
| - <0.8 | NR (NR-NR) | Reference | ||
| - 0.8–2 | 43.4 (43.4-NR) | 1.01 (0.91–2.15) | 0.81 | |
| - 5 | 33.8 (16.6–51) | 1.25 (0.66–2.39) | 0.5 | |
| - 6 | 24 (0-NR) | 1.32 (0.65–2.68) | 0.44 | |
| - >4 | 37.1 (15.4–58.9) | 1.08 (0.6–1.93) | 0.8 | |
| Ulceration | ||||
| - Absent | 57.3 (32.7–81.9) | Reference | ||
| - Present | 31.2 (19.9–42.5) | 1.29 (0.87–1.92) | 0.21 | |
| LDH | 0.47 | |||
| - <ULN | 43.7 (26.6–60.8) | Reference | ||
| - ULN—2xULN | 19.5 (11.5–27.5) | 1.37 (0.94–2) | 0.11 | |
| - 2xULN–5xULN | 79.9 (49.2–110.7) | 0.53 (0.27–1.06) | 0.07 | |
| - >5xULN | 29.7 (16.1–43.3) | 1.15 (0.79–1.66) | 0.46 | |
| Mitosis (/mm2) | 0.96 | |||
| - <1 | 48.8 (48.7-NR) | Reference | ||
| - 11 | 37.1 (14.8–59.5) | 0.93 (0.52–1.64) | 0.79 | |
| - ≥10 | 33.8(19.1–48.4) | 0.95 (0.51–1.77) | 0.87 | |
| Stage (8th AJCC edition) | 1.5 (1.01–2.37) | 0.04 | 1.5 (0.98–2.33) p = 0.06 |
|
| - IIB-IIC | NR (NR-NR) | Reference | ||
| - IIIA-IIIB | 48.3 (29.8–66.7) | |||
| - IIIA | 43.4 (6.2–80.6) | 2.66 (0.32–22.14) | 0.37 | |
| - IIIB | 48.3 (24.7–71.8) | 4.89 (0.65–36.51) | 0.12 | |
| - IIIC-IIIID | 23.9 (11.7–36.2) | |||
| - IIIC | 24 (11.2–36.7) | 7.06 (0.98–50.86) | 0.05 | |
| - IIID | 19.1 (5.7–42.7) | 7.01 (0.88–55.57) | 0.06 | |
| - IV | 31.7 (20.6–42.7) | 6.74 (0.91–49.77) | 0.06 | |
| Interval from last resection to initiation of adjuvant treatment | ||||
| <12 weeks | 43.7 (31.5–55.9) | Reference | 1.68 (1.13–2.5) p = 0.01 |
|
| >12 weeks | 14.7 (8.1–21.3) | 1.64 (1.11–2.44) | 0.01 |
* p-values <0.05 are marked in bold. AJCC: American Joint Committee on Cancer; CI: confidence interval; HR: hazard ratio; IU: international units; LDH: lactate dehydrogenase; mm: millimeters; N: number of patients; NR: not reached; mRFS: median recurrence free survival; ULN: upper limit of normality.